89Bio Inc at Bank of America Healthcare Conference Transcript
My name is Jason Zemansky. I'm one of the analysts in the healthcare sector of Bank of America. It gives me really great pleasure to introduce Rohan Palekar, CEO of 89bio. He's going to give a presentation. But if there are questions at the end, [we'll] be certainly happy to answer them.
Great. Thanks, Jason, and thanks for having us at this meeting. Here's our forward-looking statements. For those new to the story, 89bio is a company focused on liver and cardio-metabolic disorders.
A lead program, which we call pegozafermin, it is an FGF21 analog, which is a unique and differentiated FGF21 and we believe has the potential to have a significant impact in these disease states. We've shown really good efficacy data in our 1b/2a studies -- a nice safety and tolerability profile. And using our unique proprietary technology, we have -- able to dose this molecule once a week or once every two weeks.
We're developing the molecule for two very large indications
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
